Inhibrx Shares Jump 70% After Promising Chondrosarcoma Drug Trial Results

Inhibrx Biosciences shares soared 70% following the successful ChonDRAgon trial results for ozekibart, indicating significant potential in treating Chondrosarcoma, a rare bone cancer.

• Inhibrx announced that the ChonDRAgon study successfully met its primary clinical endpoint, showing a statistically significant improvement in progression-free survival for patients treated with ozekibart compared to placebo.
• The trial results demonstrated a 52% reduction in the risk of disease progression or death in chondrosarcoma patients, highlighting ozekibarts efficacy against this rare form of cancer.
• This promising data could pave the way for Inhibrx to seek approval from the Food and Drug Administration for ozekibart, enhancing treatment options for patients with chondrosarcoma.